MTI Outlook 2020: Changing China Is Opening Up For Medtech Entrants
The barriers for health-care industry entrants into China are lowering, but still not as quickly as many medtech companies would like. New structural health-care delivery plans are instilling more confidence in a market and industry that in the past have been regarded with caution.
You may also be interested in...
To the watching world, China dealt quickly and firmly with COVID-19. Seen from within, the health care system is still adapting to the pandemic, but the government is taking the longer view.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the leading global medtechs share their perspectives on the present and the future, from company and health care system standpoints.